Prot #SAV005-02: A Phase 2, randomized, double-blind, placebo-controlled study of AeroVanc for the treatment of persistent methicillin-resistant Staphylococcus aureus lung infection in cystic fibrosis patients

Project: Research project

Project Details

StatusFinished
Effective start/end date7/7/147/7/17

Funding

  • SynteractHCR, Inc. (Prot #SAV005-02)
  • Savara Inc. (Prot #SAV005-02)